News & Updates

Show Multimedia Only

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

26 May 2026 by

Icotrokinra—the first and only targeted oral peptide designed to selectively block the interleukin-23 receptor (IL-23R), which has been approved for the treatment of plaque psoriasis—shows multiple favourable signals for the treatment of ulcerative colitis (UC), according to updated data from the phase IIb ANTHEM-UC study.

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

26 May 2026

Real-world patients with perianal Crohn’s disease fare well with upadacitinib

25 May 2026

In patients with perianal Crohn’s disease (pCD) treated in routine clinical practice, the use of upadacitinib appears to have a beneficial effect on fistula outcomes, with a more pronounced effect seen for anti-TNF–naïve patients and those with shorter disease duration, according to a multicentre retrospective cohort study.

Real-world patients with perianal Crohn’s disease fare well with upadacitinib

25 May 2026

Low-volume PEG yields high-quality cleansing for bowel preparation in colonoscopy patients

24 May 2026

The use of a 1-litre (L) polyethylene glycol (PEG)-ascorbate in hospitalized adults undergoing elective colonoscopy results in higher rates of high-quality cleansing than a 2L PEG-ascorbate or 4L PEG, reports a study, noting comparable rates of adequate cleansing and high willingness to repeat.

Low-volume PEG yields high-quality cleansing for bowel preparation in colonoscopy patients

24 May 2026

Men benefit more from sigmoidoscopy screening for CRC than women

23 May 2026

Sigmoidoscopy screening has reduced the colorectal cancer (CRC) incidence and death, and these benefits tend to be more pronounced in men than in women, according to a Norway study.

Men benefit more from sigmoidoscopy screening for CRC than women

23 May 2026

Which DOAC has lower risk of complicated upper GI bleeding in Asians?

22 May 2026 by

Apixaban showed a lower 2-year risk of complicated upper gastrointestinal bleeding (UGIB) vs edoxaban and rivaroxaban, but not dabigatran, in patients without prior anticoagulant exposure, according to an industry-independent, Asian population–based cohort study conducted by researchers from the Chinese University of Hong Kong (CUHK).

Which DOAC has lower risk of complicated upper GI bleeding in Asians?

22 May 2026

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

22 May 2026 by

Treatment with guselkumab resulted in significantly higher rates of combined fistula remission at week 24 in adults with active perianal fistulizing Crohn’s disease (PFCD) compared with placebo, according to the FUZION trial presented at DDW 2026.

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

22 May 2026

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

21 May 2026 by

Results from the phase III TRIUMpH-EE study demonstrate the superiority of the novel potassium-competitive acid blocker (P-CAB) tegoprazan over the proton pump inhibitor (PPI) lansoprazole in providing faster healing of erosive esophagitis (EE) and heartburn relief.

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

21 May 2026

Rifaximin confers cognitive benefits in covert hepatic encephalopathy

19 May 2026

In the treatment of patients with covert hepatic encephalopathy, use of rifaximin results in improved cognitive performance and decreased cirrhosis-related adverse events, as shown in an open-label study.

Rifaximin confers cognitive benefits in covert hepatic encephalopathy

19 May 2026

Novel robotic colonoscopy system performs well in first-in-human study

18 May 2026 by

A robotic colonoscopy system has been shown to be safe and feasible in the first-in-human CARE study, with successful completion of the procedure achieved in all cases and no major adverse events.

Novel robotic colonoscopy system performs well in first-in-human study

18 May 2026

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

17 May 2026 by

A top-down approach of initiating treatment with infliximab plus immunomodulator upon diagnosis of Crohn’s disease (CD) reduces the risk of related abdominal surgery, as well as those of disease progression and hospitalization, as compared with the conventional step-up approach, according to long-term data from the PROFILE trial.

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

17 May 2026

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

Real-world patients with perianal Crohn’s disease fare well with upadacitinib

Real-world patients with perianal Crohn’s disease fare well with upadacitinib

Low-volume PEG yields high-quality cleansing for bowel preparation in colonoscopy patients

Low-volume PEG yields high-quality cleansing for bowel preparation in colonoscopy patients

Men benefit more from sigmoidoscopy screening for CRC than women

Men benefit more from sigmoidoscopy screening for CRC than women

Which DOAC has lower risk of complicated upper GI bleeding in Asians?

Which DOAC has lower risk of complicated upper GI bleeding in Asians?

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

Rifaximin confers cognitive benefits in covert hepatic encephalopathy

Rifaximin confers cognitive benefits in covert hepatic encephalopathy

Novel robotic colonoscopy system performs well in first-in-human study

Novel robotic colonoscopy system performs well in first-in-human study

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD